Malaysia

BMI View: Strong growth opportunities continue in Malaysia's pharmaceutical and healthcare sector, particularly in its generic drug market. This view is supported by the country's commitment... 2013-01-30

BMI View: The stronger than expected investment into Malaysia's biotechnology sector highlights not only investors' interest in the life sciences industry generally, but also affirms... 2012-11-08

BMI View: The Solomon Islands will continue to rely on aid to improve healthcare access. The country has a high burden of non-communicable and communicable diseases, which makes efficient... 2012-07-06

BMI View: The eventual establishment of the various regulatory bodies and regulation polices in Malaysia, such as the Medical Device Act and mandatory good manufacturing licences, will... 2012-06-06

BMI View: Malaysia's pharmaceutical and healthcare market growth will be driven primarily by the government-led National Key Economic Area (NKEA) blueprint, which is likely to be fulfilled... 2012-05-31

BMI View: Unless more stringent regulations are introduced, the oversight of medical devices will always lag behind the attention afforded to pharmaceuticals. We highlight that medical... 2012-05-24

BMI View: The presence of counterfeit drugs will impede the progress countries make tackling malaria. While we believe it is highly unlikely that counterfeit drug manufacturing will... 2012-05-23